Recent Activity

Loading...

ETNB

89bio Inc · NASDAQ

Performance

-5.27%

1W

-7.9%

1M

-11.4%

3M

+15.68%

6M

-22.74%

YTD

-51.08%

1Y

Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Investment Analysis Report: ETNB

Overview

ETNB is a pharmaceutical company operating in the Health Technology sector, with a market capitalization of $884,135,351. The company's industry focus is on Pharmaceuticals: Major. In this report, we will conduct a comprehensive analysis of ETNB's financial statements over the past three years, including...

See more ...

Technical Analysis of ETNB 2024-05-10

Overview:

In analyzing the technical indicators for ETNB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...

See more ...

Recent News & Updates